{"name":"Ocuwize LTD","slug":"ocuwize-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Systane Ultra UD","genericName":"Systane Ultra UD","slug":"systane-ultra-ud","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"LO2A eye drops","genericName":"LO2A eye drops","slug":"lo2a-eye-drops","indication":"Open-angle glaucoma","status":"marketed"}]}],"pipeline":[{"name":"Systane Ultra UD","genericName":"Systane Ultra UD","slug":"systane-ultra-ud","phase":"marketed","mechanism":"Systane Ultra UD is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"LO2A eye drops","genericName":"LO2A eye drops","slug":"lo2a-eye-drops","phase":"marketed","mechanism":"LO2A eye drops reduce intraocular pressure by enhancing aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}